This Article Abstract Full Text Full Text (PDF) View Related Interview Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wong, S. C. Search for Related Content PubMed Articles by Wong, S. C.

A Randomized Comparison of a Novel Bioabsorbable Vascular Closure Device Versus Manual Compression in the Achievement of Hemostasis After Percutaneous Femoral Procedures

The ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial)

S. Chiu Wong, MD^_*,_*, William Bachinsky, MD, Patrick Cambier, MD, Robert Stoler, MD, Janah Aji, MD^||, Jason H. Rogers, MD^¶, James Hermiller, MD^#, Ravi Nair, MD^_**, Herbert Hutman, MD, Hong Wang, MD, MPH for the ECLIPSE Trial Investigators

^_* Weill Medical College of Cornell University, New York, New York
Pinnacle Health at Harrisburg, Harrisburg, Pennsylvania
Morton Plant Hospital, Clearwater, Florida
Baylor Research Institute, Dallas, Texas
^|| Cooper Health Systems, Camden, New Jersey
^¶ University of California, Davis Medical Center, Sacramento, California
^# The Heart Center of Indiana, Indianapolis, Indiana
^_** University Hospitals of Cleveland, Cleveland, Ohio
Cordis Corporation, Warren, New Jersey

View larger version (15K): [in this window] [in a new window] [Download PPT slide]   Figure 1 TTH and TTA in Patients Treated With Glycoprotein IIb/IIIa Receptor Blocker In the subgroup of patients who received glycoprotein IIb/IIIa receptor blocker during their procedures, there was a significant reduction in both the mean time to hemostasis (TTH) (left) and time to ambulation (TTA) (right) in patients assigned vessel closure device (VCD) compared with patients assigned to manual compression (MC).